<DOC>
	<DOCNO>NCT00439166</DOCNO>
	<brief_summary>This study determine biomarkers find cerebrospinal fluid people Alzheimer 's disease , affect treatment two common antibiotic , doxycycline rifampicin , suggest disease-modifying effect treatment .</brief_summary>
	<brief_title>Effects Doxycycline Rifampicin Biomarkers Alzheimer 's Disease Cerebrospinal Fluid</brief_title>
	<detailed_description>Diagnostic marker cerebrospinal fluid ( CSF ) become rapidly grow research field . Potential disease-modifying drug like antibiotic rifampicin doxycycline , highlight need improve diagnostic accuracy offer potential examine treatment may actually exert clinical effect . Cerebrospinal fluid biomarkers ( 42 amino acid form β-amyloid ( Aβ ) , total tau , phosphorylated tau ) evaluate scientific study . Tau proteins consider `` state '' marker , whereas Aβ ( 1-42 ) proteins use `` stage '' marker . These CSF marker high sensitivity differentiate early AD normal aging , depression , alcohol dementia Parkinson 's disease . When biomarkers use combination medical history , clinical examination , laboratory test brain imaging , diagnostic accuracy improve . Matrix metalloproteinase ( MMP ) dysregulation think contribute variety pathological condition arthritis , cancer , atherosclerosis , aneurysms , nephritis , tissue ulcer , fibrosis . In addition , MMP involvement demonstrate pathogenesis variety CNS disorder , include bacterial viral disorder , stroke , multiple sclerosis , ALS , AD . There inflammatory response AD . This include complement activation , elevate C-reactive protein ( CRP ) , elevate pro-inflammatory cytokine ( include IL-1-β , IL-6 , TNF-α , TGF-β , S100-β ) , chemokine alteration ( IL-8 , MIP-1-α , MIP-1-β , MCP-1 ) , microglial . We measure biochemical marker Aβ ( 1-40 ) Aβ ( 1-42 ) , P-tau T-tau , matrix metalloproteinases ( MMP-2 , MMP-9 ) , pro-inflammatory cytokine ( IL-1beta , TNF-alpha ) , anti-inflammatory cytokine ( IL-4 IL-10 ) start one year treatment multi-centered , randomize , control , trial disease-modifying drug rifampicin and/or doxycycline slow progress Alzheimer 's disease affect production biomarkers .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male female Age great equal 50 year Diagnosis probable Alzheimer 's disease NINCDSADRDA criterion Standardized MiniMental State Examination score 1426 inclusive A caregiver consent monitor study medication , report patient function , bring patient visit , etc . Vision , hearing , language ability sufficient complete standardize test English . Patient consent ( legal representative consent patient ) Generally stable level health patient may reasonably expect complete 1 year trial Other neurodegenerative disease Lewy body Parkinson 's Cognitive impairment due : acute trauma , subdural hematoma , hypoxic cerebral damage , B12 deficiency , infection AIDS meningitis , cerebral neoplasia , endocrine deficiency , mental retardation Significant cerebrovascular disease multiinfarct dementia Intracranial pathology tumour Coexisting medical condition epilepsy , major psychiatric condition , depression ( Cornell Depression Dementia Scale score 12 ) , significant liver , kidney , lung , metabolic endocrine disease Clinically significant cardiac disease uncontrolled angina hypertension Antidementia treatment donepezil , galantamine , rivastigmine , memantine Enrollment trial investigational drug Antibiotic use one month last six month Allergy doxycycline rifampicin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>doxycycline</keyword>
	<keyword>rifampicin</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>biomarkers</keyword>
	<keyword>beta amyloid</keyword>
	<keyword>tau</keyword>
</DOC>